Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP.

J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5.

PMID:
9811311
3.

Detecting PML-RARalpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR.

Zhu HH, Liu YR, Qin YZ, Jiang B, Shan FX, Wu SL, Yang PD, Zhao J, Lu DP.

Chin Med J (Engl). 2007 Oct 20;120(20):1803-8.

PMID:
18028775
4.

Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.

Gau JP, Young JH, Lin TH, Yang YS.

Zhonghua Yi Xue Za Zhi (Taipei). 2000 Mar;63(3):175-81.

PMID:
10746412
5.
6.

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z.

Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35. Epub 2004 Mar 24.

7.

Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.

Côté S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C, Miller WH Jr.

Blood. 2002 Oct 1;100(7):2586-96.

8.

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL.

Blood. 2003 Apr 1;101(7):2521-8. Epub 2002 Dec 5.

10.

Monitoring of minimal residual disease in children with acute promyelocytic leukemia by RT-PCR detecting PML/RARalpha chimeric gene: a retrospective study of clinical feasibility.

Suzuki H, Imaizumi M, Sato A, Yoshinari M, Rikiishi T, Endo M, Takano T, Shimizu T, Hatae Y, Fujimoto T, Hayashi Y, Iinuma K.

Tohoku J Exp Med. 2001 Feb;193(2):127-39.

12.

The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients.

Gameiro P, Vieira S, Carrara P, Silva AL, Diamond J, Botelho de Sousa A, Mehta AB, Prentice HG, Guimarães JE, Hoffbrand AV, Foroni L, Parreira A.

Haematologica. 2001 Jun;86(6):577-85.

13.

Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.

Martinelli G, Ottaviani E, Testoni N, Visani G, Diverio D, D'Elia G, Mandelli F, Tura S.

Haematologica. 1998 Nov;83(11):985-8.

14.

[Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].

Jeanteur P.

Bull Cancer. 1998 Apr;85(4):301-3. Review. French.

15.
16.

Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.

Savickiene J, Treigyte G, Magnusson KE, Navakauskiene R.

Ann N Y Acad Sci. 2009 Aug;1171:321-33. doi: 10.1111/j.1749-6632.2009.04718.x.

PMID:
19723072
17.

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia.

Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr.

Blood. 2001 Nov 1;98(9):2651-6.

18.

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.

Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, Fouladi M, Freeman BB 3rd, Stewart CF, Houghton PJ.

Clin Cancer Res. 2006 Jan 1;12(1):223-34.

19.

Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.

Nouzova M, Holtan N, Oshiro MM, Isett RB, Munoz-Rodriguez JL, List AF, Narro ML, Miller SJ, Merchant NC, Futscher BW.

J Pharmacol Exp Ther. 2004 Dec;311(3):968-81. Epub 2004 Aug 9.

20.

Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.

Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, García Sanz R, San Miguel JF, González MG.

Haematologica. 2007 Mar;92(3):315-22.

Supplemental Content

Support Center